Skip Navigation

Clinical Trials

Clinical trials are health-related studies in people that are closely supervised and carefully follow a pre-defined protocol. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. Clinical trials may be done to see how a new treatment compares with the standard Dr. Khan, Meraida Polak, Questcor_Acthar kickoff meetingtreatment or to see if a new treatment is safe and effective for a certain condition or disease. Participation in this type of research involves treatment with an experimental treatment or medical device, which may or may not provide a direct benefit to the individual. A clinical trial must be conducted for all new treatments before the FDA will approve the treatment for the public. The Emory ALS Center is actively engaged in research projects involving clinical trials of new medications to slow the progression of ALS. Search for clinical trials www.clinicaltrials.gov

ALS patients have never had as many opportunities to participate in research projects as they have today.

We are actively recruiting for four studies listed below. Each project has its own inclusion an exclusion criteria. These criteria are spelled out on the specific clinicaltrials.gov websites (linked below).

  • Immunosuppression, nicknamed NIP.ALS (novel immunosuppression protocol) Contact Jane Bordeau, RN at jrbord@emory.edu if you are interested in participating.
  • Acthar, a study to explore the safety and tolerability of Acthar in patients with ALS. Contact Lauren Taylor, MPH at 404-778-3181 if you are interested in participating.
  • Benefit ALS (tirasemtiv) Designed to evaluate the safety, tolerability, and efficacy of tirasemtiv in people with ALS. Contact Lauren Taylor, MPH at 404-778-3181 if you are interested in participating.
  • Biomarkers The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies. Contact Latoya Shaw at Latoya.q.shaw@emory.edu if you are interested in participating.
  • Phase II ALS Stem Cell Trial, is a first-in-human trial of spinal derived stem cells transplanted into the spinal cord of patients with ALS. The goal of the study is to see if the cells and the procedure to transplant them are safe. Contact Jane Bordeau, RN at jrbord@emory.edu .
Done